Stay updated on Betalutin in Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Betalutin in Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Betalutin in Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoChange DetectedDifference0.5%
- Check23 days agoChange DetectedThe page has removed detailed descriptions of a Phase 1 study for a treatment of relapsed/refractory diffuse large B-cell lymphoma, including inclusion and exclusion criteria, while adding a new revision number and a specific EudraCT number.SummaryDifference36%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check45 days agoChange DetectedDifference0.2%
Stay in the know with updates to Betalutin in Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Betalutin in Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial page.